 A phase 23 trial failure in the MDD indication of PRAX-114 allows this biotech to shift focus over to PRAX-944 for Essential tremors and other preclinical drugs. Results from the phase 2b Essential1 study using PRAX-944 for treatment of patients with essential tremors expected 2nd half of 2022; preliminary results already released from phase 2a study. 